Compare BBBY & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBBY | ASMB |
|---|---|---|
| Founded | 1971 | 2005 |
| Country | United States | United States |
| Employees | 389 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 453.2M | 442.9M |
| IPO Year | N/A | 2010 |
| Metric | BBBY | ASMB |
|---|---|---|
| Price | $5.72 | $22.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $8.00 | ★ $44.20 |
| AVG Volume (30 Days) | ★ 2.3M | 170.1K |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.35 | N/A |
| Revenue Next Year | $7.11 | $638.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.26 | $15.84 |
| 52 Week High | $12.65 | $39.71 |
| Indicator | BBBY | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 51.63 | 30.06 |
| Support Level | $5.43 | $20.23 |
| Resistance Level | $6.11 | $31.21 |
| Average True Range (ATR) | 0.46 | 1.66 |
| MACD | -0.03 | -0.55 |
| Stochastic Oscillator | 54.98 | 4.80 |
Bed Bath & Beyond Inc is an e-commerce-focused retailer with an affinity model that owns or has ownership interests in various retail brands, offering products and services that enable its customers to enhance everyday life through quality, style, and value. The company currently owns Bed Bath & Beyond, Overstock, buybuy BABY, and other related brands and websites, as well as a blockchain asset portfolio. Its e-commerce platforms, www.bedbathandbeyond.com and www.overstock.com, are targeted at customers seeking various products such as furniture, bedding, area rugs, tabletop and cookware, decor, storage, jewelry, etc, at affordable prices. In addition to products, the company also offers add-on services across platforms, including warranties, shipping insurance, and installation services.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.